Metformin has been in clinical use for the management of type 2 diabetes for more than 60
years and is supported by a vast database of clinical experience: this includes evidence for …

One in every three deaths worldwide is caused by cardiovascular diseases (CVDs),
estimating a total of 17.9 million deaths annually. By 2030, it is expected that more than 24 …

Endothelial dysfunction (ED) is characterized by imbalanced vasodilation and
vasoconstriction, elevated reactive oxygen species (ROS), and inflammatory factors, as well …

Formononetin (FMNT), a flavonoid identified from the Chinese herb Astragalus
membranaceus, possesses anti-inflammatory or anti-oxidative properties in different human …

Introduction For a long time, metformin has been the first-line treatment for glycemic control
in type 2 diabetes; however, the results of recent cardiovascular outcome trials of sodium …

Blueberries are rich in nutrients and (poly) phenols, popular to consumers, and a major
agricultural crop with year-round availability supporting their use in food-based strategies to …

Metformin has been used as an oral anti-hyperglycaemic drug since the late 1950s;
however, following the release in 1998 of the findings of the 20-year United Kingdom …

Nitric oxide (NO) is a key molecule in cardiovascular homeostasis and its abnormal delivery
is highly associated with the occurrence and development of cardiovascular disease (CVD) …

High gestational weight gain (GWG) is a cardiovascular risk factor and may disturb neonatal
endothelial function. Long non‐coding RNAs (lncRNAs) regulate gene expression …

Endothelial dysfunction (ED) has a substantial role in the pathogenesis of atherosclerosis
and other vascular diseases. Multiple risk factors, including smoking, hyperlipiadaemia and …